LONDON, Aug 2 (Reuters) - AstraZeneca’s drug Axanum -- a combination of low-dose aspirin and the active ingredient in Nexium -- has won a positive agreement for approval in 23 European Union states and Norway.
The medicine is designed for use by patients at high risk of heart attacks or strokes who are also at increased risk of stomach ulcers. Aspirin can provoke ulcers and gastrointestinal bleeding.
AstraZeneca said on Tuesday it would work with health authorities to secure reimbursement decisions and get Axanum onto formularies to make the drug available to patients as soon as possible. (Reporting by Ben Hirschler)